Cancer clinical trials in the region Auvergne-Rhône-Alpes

301 currently recruiting clinical trials

If you are a doctor and would like find matching clinical trials for you patients, create an account or log in

If you are a patient and would like to know if you may participate in a clinical trial, please consult your doctor so that he can send your file to a matching trial

Phase 1 / Phase 2 Lung cancer #NCT04585750 #2023-504251-27-00

[PYNNACLE] Evaluation du PC14586 chez les patients atteints de tumeurs solides avancées hébergeant une mutation TP53 Y220C

Locally Advanced Metastatic TP53 1 2 3 or more

KRAS G12C KRAS non G12C Systemic Treatment-Naive

Centre Léon Bérard (Lyon), Centre Jean Perrin (Clermont Ferrand )

PMV Pharmaceuticals, Inc

Phase 1 / Phase 2 Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Stomach and esophageal cancer #NCT04585750 #2023-504251-27-00

[PYNNACLE] Evaluation du PC14586 chez les patients atteints de tumeurs solides avancées hébergeant une mutation TP53 Y220C

Locally Advanced Metastatic TP53 1 2 3 or more

KRAS G12C KRAS non G12C Systemic Treatment-Naive

Centre Léon Bérard (Lyon), Centre Jean Perrin (Clermont Ferrand )

PMV Pharmaceuticals, Inc

Phase 1 / Phase 2 Prostate cancer #NCT04585750 #2023-504251-27-00

[PYNNACLE] Evaluation du PC14586 chez les patients atteints de tumeurs solides avancées hébergeant une mutation TP53 Y220C

Metastatic Castration-resistant TP53 1 2 3 or more

KRAS G12C KRAS non G12C Systemic Treatment-Naive

Centre Léon Bérard (Lyon), Centre Jean Perrin (Clermont Ferrand )

PMV Pharmaceuticals, Inc

Phase 1 / Phase 2 Breast cancer #NCT04585750 #2023-504251-27-00

[PYNNACLE] Evaluation du PC14586 chez les patients atteints de tumeurs solides avancées hébergeant une mutation TP53 Y220C

Locally Advanced Metastatic TP53 1 2 3 or more

KRAS G12C KRAS non G12C Systemic Treatment-Naive

Centre Léon Bérard (Lyon), Centre Jean Perrin (Clermont Ferrand )

PMV Pharmaceuticals, Inc

Phase 1 / Phase 2 Colon cancer Rectal cancer #NCT04626635 #2022-501234-37-00

[COMBINE-EGFR-1] Essai visant à déterminer la sécurité du REGN7075 et son efficacité en association avec le CEMIPLIMAB chez les participants adultes atteints de cancers avancés

Metastatic MSS/pMMR 1 2 3 or more

Systemic Treatment-Naive Immunotherapy

Hôpital Lyon Sud - Hospices Civils de Lyon (Pierre-Bénite), Centre Léon Bérard (Lyon), Centre Jean Perrin (Clermont Ferrand )

Regeneron Pharmaceuticals

Phase 1 / Phase 2 Lung cancer #NCT05118789

[ARROS-1] Etude du NVL-520 chez des patients atteints d'un cancer du poumon non à petites cellules avancé et d'autres tumeurs solides hébergeant un réarrangement de ROS1 - Cohortes 2b, 2c et 2d

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic ROS-1 1 2 3 or more Targeted therapy

Systemic Treatment-Naive

Centre Léon Bérard (Lyon)

Nuvalent Inc.

Phase 1 / Phase 2 Lung cancer #NCT05118789

[ARROS-1] Etude du NVL-520 chez des patients atteints d'un cancer du poumon non à petites cellules avancé et d'autres tumeurs solides hébergeant un réarrangement de ROS1 - Cohorte 2a

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic ROS-1 None 1 Systemic Treatment-Naive Immunotherapy Chemotherapy

Targeted therapy

Centre Léon Bérard (Lyon)

Nuvalent Inc.

Phase 1 / Phase 2 Bladder / Urinary Tract / Urethral cancer #NCT05706129 #2023-504254-35-00

Étude du [68Ga]Ga-DPI-4452 et du [177Lu]Lu-DPI-4452 chez des patients atteints de tumeurs solides localement avancées ou métastatiques non résécables - Parties B, C et E

Urothelial carcinoma Locally Advanced Metastatic 1 2 3 or more Immunotherapy Chemotherapy Antibody Drug Conjugates (ADC)

Systemic Treatment-Naive

Centre Léon Bérard (Lyon), Centre Hospitalier Universitaire de Grenoble (La Tronche), Centre Jean Perrin (Clermont Ferrand )

Debiopharm International SA

Phase 1 / Phase 2 Prostate cancer #NCT04104776 #2023-508002-20-00

Etude du CPI-0209 chez des patients atteints de tumeurs solides et de lymphomes avancés - Cohorte M6

Metastatic Castration-resistant 1 2 3 or more Chemotherapy Hormone therapy

Systemic Treatment-Naive

Centre Léon Bérard (Lyon)

Constellation Pharmaceutique

Phase 1 / Phase 2 Breast cancer Lung cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer #NCT04104776 #2023-508002-20-00

Etude du CPI-0209 chez des patients atteints de tumeurs solides et de lymphomes avancés - Cohorte M1

Urothelial carcinoma Locally Advanced Metastatic ARID1A 1 2 3 or more

Systemic Treatment-Naive

Centre Léon Bérard (Lyon)

Constellation Pharmaceutique